Item 8.01 Other Events
We met with investors and potential partners to discuss ARTIVedaTM. The information is filed herewith.
Press release
On
ARTIVeda is Mateon's lead Ayurvedic drug against COVID-19 in
? No adverse events were reported that required discontinuation of treatment ? A majority of the 60 patients who received ARTIVeda plus Standard of Care (SOC) recovered faster than those who received SOC alone, with SOC defined as treatment with Remdesivir, Ivermectin, Dexamethasone, Heparin, as well as Paracetamol, B complex, Vitamin-C, and Zinc. ? The median time to asymptomatic WHO scale of 1 was 5 days for ARTIVeda plus SOC as compared to 14 days for SOC alone. The differences were statistically significant meaning unlikely to happen by chance. ? The trend was more pronounced with higher initial disease status. Log rank statistics: WHO-scale 2,3,4: p= 0.0369 /RR = 1.476 (0.8957-2.433), WHO-scale 3,4: p= 0.026/ RR = 1.581 (0.9094-2.747), WHO-scale 4: p= 0.0043/ RR = 2.038 (0.9961-4.168). RR = rate ratio for recovery.
The ARTI-19
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. Exhibit No. Description Incorporation by reference 99.1 ARTIVedaTM Product Information Filed herewith. 99.2 Press release - Interim Analysis of ARTI-19 Filed herewith -2-
© Edgar Online, source